NCT02122861View on ClinicalTrials.gov

Phase 1 Study of Intradermal LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 30, 2014

Primary Completion Date

November 14, 2018

Study Completion Date

December 15, 2018

Conditions

Melanoma - Currently EnrollingNon-small Cell Lung Cancer - Enrollment CompletedSarcoma - Enrollment Completed

Interventions

BIOLOGICAL

ID-LV305

pembrolizumab

Trial Locations (7)

29605

Greenville Health System, Greenville

55905

Mayo Clinic, Rochester

77030

MD Anderson Cancer Center, Houston

94115

San Francisco Oncology Associates, San Francisco

98102

Seattle Cancer Care Alliance, Seattle

06520

Yale University, New Haven

02215

Dana Farber Harvard Cancer Center, Boston

All Listed Sponsors

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

INDUSTRY

NCT02122861 - Phase 1 Study of Intradermal LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1 | Biotech Hunter | Biotech Hunter